In the News

/In the News

Botox Alternative Considered for Pain Therapy Treatment

A drug’s early success into glabellar frown line studies is leading to its clinical consideration for pain management and therapy. Botulinum neurotoxin serotype E (EB-001), a potential alternative to botulinum neurotoxin serotype A (BOTOX) for frown line treatment, will be using Phase II trial data to set dosing for Phase II pain therapy indication studies in 2 models. [...]

2018-05-03T21:05:44+00:00August 13th, 2017|In the News|

Bonti Announces Topline Results of EB-001 Phase 2A Clinical Study

Bonti, a privately-held, clinical-stage biotechnology company, today announced topline results of the first clinical study of its lead product candidate, EB-001, in glabellar (frown) lines. The study achieved its objectives and confirmed both favorable safety and the expected clinical efficacy profile. EB-001 is a novel serotype E botulinum neurotoxin with a unique efficacy profile, characterized by fast onset of action [...]

2018-05-03T21:05:55+00:00August 11th, 2017|In the News|

Time Magazine Spotlights Neurotoxins

Time Magazine Spotlights Neurotoxins’ Vast Medical Treatments Breadth With Botox® Cover Story. Forget wrinkles. Botox is now being used to treat migraines, depression, twitching eyes, overactive bladders, sweaty palms and more. Some call it a marvel of medicine; others caution the risks are still unknown. Inside the exploding business and strange science of Botox January 19, 2017

2018-05-03T21:06:57+00:00April 8th, 2017|In the News|